Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Stage III Colon Cancer

Trial Name: : A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer.

Protocol ID: C80702


  • Histologically documented adenocarcinoma of the colon. 
  • Tumors must have been completely resected.
  • Patients are not eligible if they use NSAIDs at any dose or aspirin at more than 325 mg at least three times per week on average. Low-dose aspirin not exceeding 100 mg/day is permitted.
  • No previous or concurrent malignancy, except treated basal cell or squamous cell cancer of skin, treated in situ cervical cancer, treated lobular or ductal carcinoma in situ in one breast, or any other cancer for which the patient has been disease-free for at least 5 years.
  • No known allergy to platinum compounds
  • No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDs.
  • Non-pregnant and not nursing. Men and women of childbearing potential must agree to employ adequate contraception for the duration of chemotherapy and for as many as 6 months after the completion of chemotherapy due to the unknown teratogenic effects of FOLFOX on the developing fetus.
  • At least 18 years of age or older.

Must meet required laboratory values.

Enrollment: • As many as 2, 500 people will take part in this study at several medical centers.


  • Taking part in this study may or may not make your health better. While doctors hope that adding celecoxib to FOLFOX may decrease the risk of cancer recurrence compared to FOLFOX alone, there is no proof of this yet. Furthermore, while doctors hope that the shorter course of FOLFOX (6 treatments) will be as effective as a longer course of FOLFOX (12 treatments), there is no proof of this yet. We do know that the information from this study will help doctors learn more about these drugs as a treatment for cancer. This information could help future cancer patients.


These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Jun 3, 2011

Updated: Oct 16, 2014

« Return to Trials